Parnax Lab

Parnax Lab LT Debt/Equity

The Long-Term Debt to Equity Ratio of Parnax Lab (506128.BO) as of Nov 2, 2026 is 0.32. In the previous year, Long-Term Debt to Equity Ratio was 0.42 — a change of -24.51% (lower).

LT Debt/Equity

0.32

YoY

-24.51%

Last updated:

Long-Term Debt to Equity Ratio of Parnax Lab is 2025 0.32 . Long-Term Debt to Equity Ratio of Parnax Lab was 2024 0.42 . It decreases by -24.51% lower compared to the previous year.

The Parnax Lab LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2018
0.51 INR
Jan 1, 2019
0.60 INR
Jan 1, 2020
0.61 INR
Jan 1, 2021
0.53 INR
Jan 1, 2022
0.43 INR
Jan 1, 2023
0.25 INR
Jan 1, 2024
0.42 INR
Jan 1, 2025
0.32 INR
The Parnax Lab LT Debt/Equity history
YEARLT Debt/EquityYoY
0.32-24.51%
0.42+69.57%
0.25-42.20%
0.43-18.92%
0.53-13.13%
0.61+0.32%
0.60+17.63%
0.51-22.75%
0.66-17.68%
0.81-20.80%
1.02+5.03%
0.97—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Parnax Lab Stock analysis

What does Parnax Lab do? Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems. Parnax Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Parnax Lab stock

Long-Term Debt to Equity Ratio of Parnax Lab is 0.32 in 2025.

Long-Term Debt to Equity Ratio of Parnax Lab changed from 0.42 to 0.32, representing a -24.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Parnax Lab since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Parnax Lab with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Parnax Lab

All Key Metrics — Parnax Lab